Mikhail Blagosklonny is a renowned Oncologist Professor at Roswell Park Cancer Institute. He has a Ph.D. in Experimental Medicine and Cardiology as well as a Master’s degree in Internal Medicine. Due to his excellent work in these fields, Mikhail was not only appointed as an Associate Professor of Medicine at New York Medical College but also a Senior Scientist in Ordway Research Institute. Blagosklonny is passionate about research work on therapies that protect normal body cells from targeted cancer treatment procedures and cancer-related tissue damages. He also has an interest in the process of aging and development of anti-aging drugs. Mikhail is known for his tangible contribution and advocating for the use of Rapamycin in order to increase human lifespan. Rapamycin is commonly known in pharmacy market as Rapamune or Sirolimus. It is a revolutionary cancer drug and is also used to prevent rejection of organ transplant.
The drug was first isolated from bacterium sample in Easter Island in 1972. It was originally used to treat a fungal infection until a research was conducted and showed that Rapamycin had incredible antiproliferative and immunosuppressive properties.Rapamycin has proven to be one of the best medicines due to its unique properties that make it outweigh other medications. For starters, compared to other immunosuppressive drugs, Rapamycin has low side effects and toxicity level on the kidney. It is recommended for people suffering from hemolytic-uremic syndrome after a kidney transplant. Besides, it reduces kidney re-infection and is less toxic to the kidney. Mostly, the drug is used to treat Lymphangioleiomyomatosis (LAM), coating coronary stent in addition to cancer. Studies showed that Rapamycin prevents the growth of tumor in areas such as the brain, kidney, heart, and other vital organs. As a result, it is also used to treat facial angiofibroma, Alzheimer’s disease, muscular dystrophy, systematic lupus erythematosus (SLE), and lengthening lifespan.
Mikhail Blagosklonny is aiming at finding a way to treating cancer that is cheaper and effective compared to the current expensive and torturing cancer treatment procedures. He is specifically focused on studying both cancer and aging. More interestingly, Mikhail hopes that his progressive work in medicine will be an inspiration to other people around the world to carry on with his research work in order to bring more transformation in cancer treatment. He believes that cancer treatment will be affordable to everyone and not a costly treatment only available for the rich. \Additionally, he hopes to discover a way in which cancerous cells will be eliminated without damaging the normal cells that assist the body to recover from prolonged effects of cancer treatment. He is still carrying on with his medical research and continues to contribute significantly in the field of Oncology. Mikhail Blagosklonny is not only an influential researcher but also an expert who inspires his peers and students with interest in expanding and continuing his research. The interesting medical work of Mikhail Blagosklonny has drawn a lot of attention within the field of medicine, and everyone hopes it will be a breakthrough to cancer patients.
The current President and CEO of InnovaCare Health is Dr. Richard Shinto. Dr. Shinto is one of the most qualified leaders at InnovaCare. His career is adorned with accomplishments and accommodations. Within the first few years of joining InnovaCare, Dr. Shinto earned InnovaCare the number one spot for managed care providers in Penelope Kokkinides .Before joining InnovaCare, Dr. Shinto another company, Aveta Inc., until its sale in 2012. He worked for that company for four years. Before that, Dr. Shinto worked at several institutions that still exist today. He’s worked hard for more than 20 years in the managed care industry, specializing in operational healthcare.
It’s hard to say whether Dr. Shinto always knew what he wanted to do when he grew up. And honestly, it doesn’t really matter. Dr. Shinto is one of the most accomplished physicians in his field. To this day, he’s still a practicing internist and pulmonologist in Southern California.Penelope Kokkinides was recently named the company’s new Chief Administrative Officer. This is Kokkinides’s second time working for the company. Prior, she served as COO, but upon her return, that position was filled with another qualified professional. Kokkinides has not let that change of position affect her work ethic.Kokkinides is one of the industry’s best at reconstructing an entire company. She spent more than 20 years specializing in government programs. Her experience in the managed care industry is unrivaled. She’s played a significant role in the development and implementation of many new health models at many different companies.Her years away from InnovaCare were well-spent. Immediately following her departure from InnovaCare, Kokkinides took the Executive VP and COO positions at Centerlight Healthcare.
But her biggest accomplishment may have come when she worked at AmeriChoice. There, she created the company’s best health model.It’s sad to say that there aren’t many companies like InnovaCare. Most managed care institutions only care about profit margins. InnovaCare puts their patients first; always. Everything InnovaCare and its subsidiaries do all go toward providing the best quality medical care possible. Everyone at InnovaCare focuses on creating cost-effective and innovative models of healthcare.Today’s healthcare environment is so complex that it’s hard for patients to fully trust their healthcare providers. That’s why it’s so important that InnovaCare builds strong patient-provider relationships.
On the 24th of April, 2017, PE HUB Network did a press release announcing Dr. Molly He as a venture partner with Foresite Capital. The press release highlights Dr. He’s extensive experience in pharmaceutical and genomic research. Specifically, it mentions her time at Illumina and Pacific Biosciences where she served in senior leadership positions directing improvements in protein reagent development. The release goes on to mention that Dr. He has a Bachelor’s degree in biochemistry from Nankai University and a Ph.D. in protein biophysics from the University of California, Los Angeles.http://www.insidermonkey.com/hedge-fund/foresite+capital/740/
Jim Tananbaum, M.D., CEO and Managing Director of Foresite Capital, gives Dr. Molly He high praise in the press release. He stated that “her extensive experience in genomics and drug development make her an invaluable resource to Foresite.” He also went on to cite her strong leadership skills. Foresite Capital provides capital and support to help companies with transformative products and services become healthcare leaders. Their focus is on the development and commercialization of transformative medical products that address critical healthcare needs.
Dr. Jim tananbaum founded Foresite Capital in 2011 with the aim to transform patient care. They are based in San Francisco, California. Since its founding, Foresite Capital has invested heavily in biotech and med tech companies both public and private. The firm has experienced a great deal of new IPO successes which include Juno Therapeutics and Bellicum Pharmaceuticals. Tananbaum believes the healthcare sector is experiencing unprecedented innovation. Foresite Capital has benefited a great deal by investing in the latest innovations in transformative health care. It can be argued that Foresite Capital’s ventures have also led to better patient outcomes.
Dr. Jim Tananbaum has over 25 years of experience in entrepreneurial healthcare investment. Prior to founding Foresite Capital he cofounded two successful biopharmaceutical companies. GelTex Pharmaceuticals and Theravance Inc. were both cofounded by Jim Tananbaum. Both companies were acquired and have a combined market capitalization of over $3 billion. Jim Tananbaum’s entrepreneurial success has landed him on Forbes’ Midas List of Top Tech Investors for the last 3 years. Tananbaum holds a B.S.E.E. from Yale University and an MD from Harvard Medical School. He also holds an MBA from Harvard Business School.
Read more: http://www.bizjournals.com/sanjose/news/2014/04/07/foresites-jim-tananbaum-sees-sloppiness-in-rush-to.html
Follow him on Twitter